Back
ESC Premium Access

Systemic immune-inflammation index predicts major adverse cardiovascular events in patients with ST-elevation myocardial infarction

Session: Acute Coronary Syndromes ePosters
Topic: Epidemiology, Prognosis, Outcome
Speaker: Doctor A. Denegri (Parma, IT)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Andrea Denegri

Hospital of Parma, Parma (Italy)
0 follower

205 more presentations in this session

Optimal timing of intervention in NSTE-ACS without pre-treatment

Speaker: Doctor I. Almeida (Barreiro, PT)

Access
Abstract
Slides
0
Thumbnail

Antithrombotic strategy in patients with atrial fibrillation and acute coronary syndrome

Speaker: Doctor I. Almeida (Barreiro, PT)

Access
Abstract
Slides
0
Thumbnail

Drug-eluting balloon catheters in the treatment of left main coronary artery bifurcation lesions: 4-years follow-up

Speaker: Associate Professor D. Maximkin (Moscow, RU)

Access
Abstract
Slides
0
Thumbnail

Clinical outcomes by angiographic type of spontaneous coronary artery dissection

Speaker: Doctor R. Mori Junco (Madrid, ES)

Access
Abstract
Slides
0
Thumbnail

Clinical impact of CREDO-kyoto risk score on in-hospital bleeding in patients with acute coronary syndrome

Speaker: Doctor Y. Minematsu (Saga, JP)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Acute Coronary Syndromes ePosters

Speakers: Doctor A. Denegri, Doctor I. Almeida, Doctor I. Almeida, Associate Professor D. Maximkin, Doctor R. Mori Junco...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

Open Access

The Clock is Ticking: The Imminent Need to Re-evaluate Standard of Care in the 90-Day High-Risk Post-AMI Period.

29 August 2021

ESC Premium Access

A veteran athlete with coronary artery disease: how to implement the guidelines and take-home message.

29 August 2021

ESC Premium Access

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

27 August 2021

ESC 365 is supported by

logo Novo Nordisk